Related Experiment Videos
Genetic approaches for biologic therapy of cancer
A Gambotto1, V Cicinnati, P D Robbins
1Department of Molecular Genetics and Biochemistry, University of Pittsburgh, School of Medicine, Pittsburgh, Pennsylvania 15219, USA.
Abstract:
Recently, there has been an increase in the types of biological therapeutic approaches developed for the treatment of cancer. This rapid advance in the biological therapy of cancer is due in part to advances in the field of molecular and cell biology as well as in the development of gene transfer systems. In particular, a better understanding of the mechanism of antigen presentation and T lymphocyte activation has resulted in the development of new immunotherapeutic strategies targeting tumor-associated antigens (TAA). The discovery of dendritic cells (DC) as potent antigen presenting cells and the development of methods for their use in immunotherapeutic regimens has led to novel approaches for treating cancer. Furthermore, the identification of genes encoding TAA and their peptide products, which are recognized by T lymphocytes in the context of major histocompatibility complexes class I and class II molecules, has led to the development of DNA-based vaccines against defined tumor antigens. Cytokines have been shown to be important adjuvant tools for immunization protocols by directing a T helper response favorable for an adequate cytotoxic T lymphocyte-mediated immune response. Novel gene transfer technologies have made it possible to employ a wide range of gene delivery systems, either viral or nonviral based, in anticancer therapies. Current immunotherapeutic strategies, including the use of DC transduced with genes coding for tumor antigens and cytokines delivered by recombinant viral vectors, have shown promise in animal tumor models.
Insights
Advances in molecular biology and gene transfer have spurred new cancer immunotherapies. These strategies, including dendritic cell (DC) therapies and DNA vaccines targeting tumor antigens, show promise in preclinical models.
Area of Science:
- Oncology
- Immunology
- Molecular Biology
- Gene Therapy
Background:
- Biological therapies for cancer are rapidly advancing due to progress in molecular and cell biology.
- Improved understanding of antigen presentation and T lymphocyte activation has driven the development of novel immunotherapeutic strategies.
- Dendritic cells (DCs) are recognized as potent antigen-presenting cells, offering new avenues for cancer treatment.
Purpose of the Study:
- To review recent advances in biological therapies for cancer treatment.
- To highlight the role of molecular biology, gene transfer, and immunology in developing novel cancer treatments.
- To discuss the potential of dendritic cell-based immunotherapies and DNA vaccines targeting tumor-associated antigens.
Main Methods:
- Review of current literature on biological cancer therapies.
- Discussion of immunotherapeutic strategies targeting tumor-associated antigens (TAA).
- Exploration of dendritic cell (DC) applications and DNA-based vaccines.
- Analysis of gene transfer technologies (viral and nonviral) for anticancer therapies.
Main Results:
- New immunotherapeutic strategies targeting TAAs have been developed based on understanding TAA recognition by T lymphocytes.
- Dendritic cell (DC) based immunotherapies represent a novel approach to cancer treatment.
- DNA-based vaccines against defined tumor antigens have emerged.
- Cytokines are valuable adjuvants in immunotherapy, directing T helper responses.
- Gene transfer technologies enable diverse viral and nonviral gene delivery systems for cancer therapy.
Conclusions:
- Current immunotherapeutic strategies, including DC-based therapies and DNA vaccines, show promise in preclinical cancer models.
- Advances in gene transfer technologies are crucial for developing effective biological therapies.
- Targeting tumor-associated antigens and leveraging immune responses are key to successful cancer immunotherapy.